Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luz Vazquez

Neurology Port St Lucie, FL Medical Doctor

NPI 1568418325 CMS profile 436138

10023 S US Highway 1 Ste B, Port St Lucie, FL 34952

Open in the dashboard

General payments

$7,905

315 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luz Vazquez of Port St Lucie, FL is reported in the CMS Open Payments database as having received $7,905 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,827 100
2024 General $1,785 69
2023 General $1,287 53
2022 General $1,049 50
2021 General $386 21
2020 General $118 7
2019 General $454 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luz Vazquez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Luz Vazquez were reported at $2,827. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Luz Vazquez Neurology median Middle half National median
2019 $454 $474 $118–$2,177 $163
2020 $118 $367 $82–$2,309 $114
2021 $386 $438 $104–$2,547 $132
2022 $1,049 $442 $103–$2,388 $149
2023 $1,287 $464 $119–$2,312 $160
2024 $1,785 $468 $119–$2,323 $164
2025 $2,827 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,246 67 payments
  2. EMD Serono, Inc. $893 26 payments
  3. Neurocrine Biosciences, Inc. $468 22 payments
  4. Alexion Pharmaceuticals, Inc. $389 11 payments
  5. Eisai Inc. $372 11 payments
  6. LivaNova USA, Inc. $372 12 payments
  7. Teva Pharmaceuticals USA, Inc. $364 12 payments
  8. Novartis Pharmaceuticals Corporation $347 19 payments
  9. Pfizer Inc. $306 13 payments
  10. Otsuka America Pharmaceutical, Inc. $300 5 payments
  11. Other $2,848 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,727 312 payments
  2. Education $155 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $902 48 payments
  2. QULIPTA $701 37 payments
  3. INGREZZA $468 22 payments
  4. Mavenclad $356 3 payments
  5. Leqembi $347 9 payments
  6. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $336 10 payments
  7. ZAVZPRET $285 12 payments
  8. REXULTI $285 4 payments
  9. NURTEC ODT $282 12 payments
  10. ULTOMIRIS $248 9 payments
  11. Other $4,523 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,557

Median for Neurology: 833

Drug cost

$340,033

Median for Neurology: $202,670

Branded share of claims

23.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 19 $181,842
Nurtec Odt Rimegepant Sulfate Brand 37 $60,745
Botox Onabotulinumtoxina Brand 18 $28,824
Ubrelvy Ubrogepant Brand 15 $15,262
Pregabalin Generic 99 $5,542
Memantine Hcl Er Memantine Hcl Brand 79 $5,406
Lacosamide Generic 15 $5,318
Gabapentin Generic 144 $3,738
Levetiracetam Generic 74 $3,065
Carbamazepine Er Carbamazepine Brand 24 $2,941

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$69,894

Medicare's payments for the services billed

Medicare patients

192

Average age 75

Services billed

709

115 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 42%
Depression 41%
Ischemic heart disease 38%
COPD 26%
Chronic kidney disease 25%
Alzheimer's or dementia 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $237
$237 — —
REXULTI
  • Lundbeck LLC $113
  • Otsuka America Pharmaceutical, Inc. $27
$140 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $132
$132 — —
QULIPTA
  • AbbVie, Inc. $131
$131 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $111
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record